C
Chihiro Yamamoto
Researcher at Jichi Medical University
Publications - 54
Citations - 404
Chihiro Yamamoto is an academic researcher from Jichi Medical University. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 9, co-authored 46 publications receiving 263 citations.
Papers
More filters
Journal ArticleDOI
Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older.
Akiko Meguro,Katsutoshi Ozaki,Kazuya Sato,Iekuni Oh,Shin-ichiro Fujiwara,Rie Hosonuma,Miyuki Sasazaki,Yuji Kikuchi,Yuji Hirata,Chihiro Yamamoto,Mitsuyo Uesawa,Hiroyuki Kobayashi,Haruko Matsu,Hiroshi Okabe,Eisuke Uehara,Akinori Nishikawa,Raine Tatara,Kaoru Hatano,Chizuru Yamamoto,Tomohiro Matsuyama,Masaki Toshima,Masuzu Ueda,Ken Ohmine,Takahiro Suzuki,Masaki Mori,Tadashi Nagai,Kazuo Muroi,Keiya Ozawa +27 more
TL;DR: Three-year PFS with R-70%CHOP for patients aged 70 years and older was not significantly worse than that with full-dose R-CHop for younger patients, suggesting that R- 70% CHOP might be a reasonable choice for patients with DLBCL aged 70 year and older, especially for those with comorbidities.
Journal ArticleDOI
Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation.
Chihiro Yamamoto,Hirotomo Nakashima,Takashi Ikeda,Shin-Ichiro Kawaguchi,Yumiko Toda,Shoko Ito,Kiyomi Mashima,Takashi Nagayama,Kento Umino,Daisuke Minakata,Hirofumi Nakano,Kaoru Morita,Ryoko Yamasaki,Miyuki Sugimoto,Yuko Ishihara,Masahiro Ashizawa,Kaoru Hatano,Kazuya Sato,Iekuni Oh,Shin-ichiro Fujiwara,Masuzu Ueda,Ken Ohmine,Kazuo Muroi,Yoshinobu Kanda +23 more
TL;DR: Imatinib first was shown to be the most cost-effective approach even with the incorporation of stop TKI, and the results were robust to univariate and multivariate sensitivity analyses.
Journal ArticleDOI
CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models
Tomonori Tsukahara,Ken Ohmine,Chihiro Yamamoto,Ryosuke Uchibori,Hiroyuki Ido,Takeshi Teruya,Masashi Urabe,Hiroaki Mizukami,Akihiro Kume,Masataka Nakamura,Junichi Mineno,Kazutoh Takesako,Isabelle Riviere,Michel Sadelain,Renier J. Brentjens,Keiya Ozawa +15 more
TL;DR: The ability of CD19-CAR T-cells to home in on tumor lesions is pivotal for their anti-tumor effects in the authors' xenograft models, and therefore may enhance the efficacy of adoptive T-cell therapy for refractory B-cell lymphoma.
Journal ArticleDOI
Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement.
Kento Umino,Shin-ichiro Fujiwara,Takashi Ikeda,Yumiko Toda,Shoko Ito,Kiyomi Mashima,Daisuke Minakata,Hirofumi Nakano,Ryoko Yamasaki,Yasufumi Kawasaki,Miyuki Sugimoto,Chihiro Yamamoto,Masahiro Ashizawa,Kaoru Hatano,Kazuya Sato,Iekuni Oh,Ken Ohmine,Kazuo Muroi,Yoshinobu Kanda +18 more
TL;DR: Myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement are hematopoietic stem cell disorders with a poor prognosis, but no established standard therapy.
Journal ArticleDOI
Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies
Daisuke Minakata,Shin-ichiro Fujiwara,Takashi Ikeda,Shin-Ichiro Kawaguchi,Yumiko Toda,Shoko Ito,Shin-Ichi Ochi,Takashi Nagayama,Kiyomi Mashima,Kento Umino,Hirofumi Nakano,Ryoko Yamasaki,Kaoru Morita,Yasufumi Kawasaki,Miyuki Sugimoto,Chihiro Yamamoto,Masahiro Ashizawa,Kaoru Hatano,Kazuya Sato,Iekuni Oh,Ken Ohmine,Kazuo Muroi,Tsukasa Ohmori,Yoshinobu Kanda +23 more
TL;DR: Resolution of DIC was correlated with improvement of background hematological malignancies, and no significant differences were observed between the two SPIs.